

MEDICO REMEDIES LTD.





A WHO-GMP, ISO 9001-2015 & GOVT, RECOGNISED STAR EXPORT HOUSE

Manufacturers of Pharmaceutical Formulations

Regd. Office: 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel.: +91-22-2682 1054 / 1055 / 2683 7116

Email: medicoremedies@yahoo.com • info@medicoremedies.com • Website: www.medicoremediesindia.com • www.medicoremediesindia.net • www.tabletandcapsules.com

Date: 11th January, 2024

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai – 400001

Scrip Code: 540937

National Stock Exchange of India Limited

5th Floor, Exchange Plaza,

Bandra Kurla Complex, Bandra (East)

Mumbai-400051 **Symbol: MEDICO**

Dear Sir/Madam,

Sub: Investor Presentation for Q2 FY 2023-24

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Investor Presentation for Q2 FY 2023-24 of the Company.

Kindly take the same on records.

Thanking you,

Yours faithfully

FOR MEDICO REMEDIES LIMITED

HARESH MEHTA CHAIRMAN & WHOLE-TIME DIRECTOR DIN: 01080289

Encl: as Above



MEDICO REMEDIES LIMITED

EXCELLENCE IN HEALTHCARE EVERYDAY

Investor Presentation December 2023

Disclaimer

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Medico Remedies Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. This presentation may contain certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.



About the Company

- Established in 1994, Medico is a formulation manufacturing company with focus on anti-infective, Beta-Lactums, Cephalosporin, Antimalarial, Antiretroviral, Anti-ulcer drugs and antacids, Vitamins, Haematinics and other supplements.
- Manufacturing and Marketing capabilities in other drugs such as NSAIDS, antihistaminic, anti-diabetics, cardio vascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream & gel for various therapeutic segments.

Our Vision and Values

Values

- Customer satisfaction above all
- Quality medicine at affordable cost
- Healthy working environment for all
- Continuous upgradation and improvement

Vision

Driven by the passion to create a healthier and happier tomorrow, Medico Remedies is taking giant strides in establishing itself as a leading and preferred pharmaceutical manufacturer and supplier





Our Global Presence



Medico Remedies is counted as a trusted manufacturer, supplier and exporter of wide range of pharmaceuticals products in both General and B-Lactam categories.

The company is empowered with the latest WHO-GMP and ISO 9001-2008 certifications.

The state of the art manufacturing unit has also been approved by the National Drug Authority of Uganda, Kenya, Ghana, Nigeria and Malawi to name a few.

Our Market

Global Market:


US\$ 1.6 Trillion

India Pharmaceutical Market:

US\$ 50 Billion

India Pharmaceutical Market is likely to be touched

US\$130 billion by 2030.



Our Milestones

1994 _____ 1999-02 _____ 2016 _____ 2017


Incorporated as Medico Remedies Private Ltd

Set up Manufacturing
Facility for Beta-Lactam
and Formulation

Renewed WHO-GMP
Certification for
manufacturing facility
Purchased corporate
premises at "Hubtown
Solaris"

Renewed ISO9001:2015 Certification
for manufacturing
facility and Converted
into Public Limited
Company

Our Milestones





Our Product Portfolio

Anti Biotic & Anti Infective	Beta-lactams- Penicillins And Cephalosporins	Antifungals	Vitamins & Supplements	
oxycycline Capsules	Cefpomed 200mg	Fluconazole Capsules	Ommed-20 Capsules	
Zenof-400 (Ofloxacin Tablets 400mg)	Ampicillin 500mg	Nystatin Vaginal Tablets	Lansoprazole Capsule	
Azithromycin Tablets	Cefuroxime Axetil Tablets USP 500mg	Ketoconazole Tablets 200 mg	Ranitidine Tablets 150 mg	
Lovoxine (Levofloxacin 500mg) Tablets	Cefixime 100mg		Acikit Tablets	
Aciclovir Tablets	Cloxacillin Capsules BP 500mg		Mebendazole Tablets USP 100mg	
Chloramphenicol Capsules	Meclox (Ampicillin & Cloxacillin) Capsules		Rabzole-20	



Our Product Portfolio

Cardiovascular	Antipyretic, Analgesic, NSAIDs	Antacid, Anti-Ulcer Drugs	Antidepressants, Antipsychotics & Anti- epileptics
Bisoprolol Fumarate	Paramed-500	Folic Acid Tablets	Jamindine (Cimetidine) Tablets BP 200 mg
Artemether and Lumefantrine Tablets	Upfenac Tablets	Vitamin-B Complex Tablets	Caprilcare (Captopril) Tablets 25 mg
Nifedipine Tablets 20 mg	Doirvan-50 Tablets	Meditone Forte	Fluoxecap (Fluoxetine) Capsules USP 20 mgs
Atormed Tablets 10 mg	Voltamed Tablets 50 mg	Upfine Tablets	Bromocriptine Tablets
Lodipine (Amlodipine)	Camola Tablets	Calneed Tablets	Amitriptyline Tablets BP 25mg
Enalapril Tablets BP 20mg	Ibuprofen Tablets 400 Mg	C-Vital (Vitamin-C) Tablets	Pomtil (Chlorpromazine) Tablets BP 100mg
	Celecoxib Capsules 200 mg		Isrip (Risperidone Tablets) 2mg
	Piroxicam Capsules BP 40mg		Racex (Sod Val) Tablets BP 200 mg
	Naproxen Tablets BP 550mg		Carbamazepine Tablets 200 mg



Our Product Portfolio

Dry Syrups	Syrups	Miscellaneous	Antimalarials	
Erythromycin Oral Suspension 125mg/5ml	Tos Syrup	Carbin 5 Tablets	Quinine Sulphate Tablets	
Amoxicillin Oral Suspension 250mg/5ml	Ibuprofen Syrup 100mg/5ml	Glucosamine Sulfate Potassium Chloride Capsules	Artemether and Lumefantrine Tablets	
Ampicillin Oral Suspension 125mg/5ml	Ferrovit Syrup	Upsolone (Prednisolone) Tablets	Primaquine Phosphate	
Cefixime Oral Suspension 100mg/5ml	Med Reactin (Cyproheptadine) Syrup	Allopurinol Tablets BP 100 mg		
Dicloxacillin Oral Susp 250mg/5ml	Medivit Syrup	Salbutamol Tablets BP 2mg	Ointments & Creams	
	Paediatric Co-Trimozole Oral	Clopidogrel Tablets USP 75mg	Dolmed (Ibu) Cream	
		Citadine-4 Tablets		
		Loratadine Tablets USP 10mg	Anti-Diabetics	
		Methylprednisolone Tablets BP 16mg	Metformin Tablets BP 500 mg	
			Glibenclamide Tablets 5mg	

Our Board of Directors

Mr. Haresh Mehta, Chairman and CFO

Currently, Mr. Haresh Mehta aged 62 is the Chairman & Chief Financial Officer of our Company. He is a founding member of our Company. He now looks after the Financial and Legal departments of our Company. He holds Bachelor's Degree of Pharmacy from the University of Bombay and a diploma holder in Industrial Management from Xavier Institute of Management. He has approximately 39 years of experience pharmaceutical industry.

Mr. Harshit Mehta, Managing Director

Presently, Mr. Harshit Mehta aged 32 is the Managing Director of our Company and is heading Marketing and Export departments of our Company. He holds Bachelor's Degree of Pharmacy from the University of Mumbai and also holds Diploma in Family Business Management from S P Jain Institute, Mumbai. He has around 16 years of experience in pharmaceutical industry.

Mr. Rishit Mehta, Whole-time Director

He is the Whole-time Director of our Company and looks after the Production (Technical) and Quality Control department of our Company. He holds Bachelor of Engineering, Chemical from University of Mumbai and Master's Degree of Science from the Rutgers, the State University of New Jersey. He has around 10 years of experience in the pharmaceutical Industry.

Mrs. Rita Mehta, Non-Executive Director

She is the Non-Executive Director of our Company. She has completed Bachelor of Commerce from Mumbai University and she has around 17 years of experience in the pharmaceutical Industry. Prior to joining our Company, she has 2 years of experience in Banking Sector and was also lecturer in Shreemati Nathibai Damodar Thackersey ('SNDT') College for 2 years. Currently, she heads the office administration department of our company.

Our Board of Directors

Mr. Deepesh Rajesh Shah, Independent Director

Presently, Mr. Deepesh Shah is Additional Non-Executive Independent Director of our Company. He has obtained his Bachelors of commerce degree from the University of Mumbai in the year 1999. He has worked at senior designations at various big companies in Media & Communication Industry like STAR India (P) Ltd, Glob sport Digital India (P) Ltd, and Fox Star Studios India (P) Ltd between the periods of March 2001 to September 2014. Currently the founder of Yellow Integrated Content & Communication LLP which is a Self funded venture and broke-even, profitable within the first 12 months and today is one of the leading consultancy firms in the Hindi film and regional film industry.

Mr. Bharat Rathod, Non-Exec. Independent Director

Recently, Mr. Bharat Rathod has been appointed as the Additional Non-Executive Independent Director of our Company. He has completed Diploma in Plastic Engineering from Board of Technical Examinations, Maharashtra State. He has around 35 years of experience as Plastic Engineer. Currently, sole proprietor of Start lite Industries engaged

Mr. Ramesh Rughani, Non-Exec. Independent Director

He aged 66 years, has been appointed as the Additional Non- Executive Independent Director of our Company. He is a fellow member of The Institute of Chartered Accountants of India. Currently he is director of 'Khyati Advisory Services Limited' and 'Sanpras Healthcare Private Limited' and also designated Partner of 'Nascent Global Impex LLP'. He has around 30 years of experience in export field and partner in Delta Cut tools a firm engaged in machining of all types of steel items

Mr. Deepak Vekaria, Non-Exec. Independent Director


He has been appointed as the Additional Non-Executive Independent Director of our Company. He is a fellow member of The Institute of Chartered Accountants of India. He has around 3 decades of experience and has established a proprietorship concern named "Deepak Vekaria & Associates" since February 2005. In the past, he was on the panel of BSE Investigation & Surveillance Department; was a member of SEBI Resource Person and was a founding member of SEBI recognized Investor Protection and Education Fund.

Our Certification
















Q2FY24 Financial Performance





Net Profit Up by 84% QoQ



Quarterly Snapshot

INR Cr	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24
Sales	33.1	40.5	38.9	28.0	31.5	42.4
Expenses	33.3	37.3	35.5	24.8	29.0	39.3
EBITDA	-0.2	3.1	3.4	3.2	2.5	3.1
Other Income	1.6	1.6	0.9	0.0	0.3	1.0
Depreciation	0.6	0.7	0.7	0.7	0.7	0.7
Interest	0.2	0.2	0.2	0.2	0.2	0.2
Profit before tax	0.7	3.9	3.3	2.3	1.9	3.1
Тах	0.3	1.0	1.1	0.5	0.6	0.7
Net profit	0.4	2.9	2.3	1.8	1.3	2.4
ОРМ	-1%	8%	9%	11%	8%	7%

Subdued performance in Q2 and H1 of FY24 mainly because of some countries like Myanmar business reduced due to political situation also less demand in other places, and also forex issues everywhere.

Key Growth Drivers


- > Revenue growth guidance: 15-20%
- In H1FY24, started business in Somalia and won few big tender in Burundi. Sri Lanka business picked up very well. Planning to add 2-3 countries every year.
- Key product in pipeline are Ointment and Cephalosporin. Many Products are under registration for existing and new geographies
- EBITDA Margin would improve to mid-high teen from high single digit on scaling ointment lines
- Plan to add more registration like PIC/S, US FDA, and EU which opens up regulatory markets
- New plant for Cephalosporin injections, tablets and dry syrup (trying for PIC/S and EU GMP Level)
- > Addition of Amoxyclav (Augmentin)line to existing plot 8
- Expanding capacity in Tablets and Caps plant

5 Year Financial Performance


Revenue CAGR Growth 18% over FY18-FY23




Profitability Margin Improvement Continues...




Healthy Return Ratio



Healthy Profitability







Income Statement

INR cr	FY18	FY19	FY20	FY21	FY22	FY23
Sales	61	98	89	122	121	140
Expenses	58	95	86	117	114	131
Operating Profit	3	3	3	5	7	10
Other Income	1	2	2	1	2	4
Depreciation	1	2	2	2	2	3
Interest	2	1	1	1	1	1
Profit before tax	2	2	2	4	6	10
Tax	1	1	1	1	2	3
Net profit	1	2	2	3	5	7
EPS (Rs)	0.15	0.19	0.20	0.31	0.58	0.87

Balancesheet

Particulars (Inr cr)	FY18	FY19	FY20	FY21	FY22	FY23
Share Capital	4	4	4	4	17	17
Reserves and Surplus	23	24	26	28	21	27
Total Equity	27	28	30	33	37	44
Long Term Borrowings	2	2	5	5	1	0
Deferred Tax Liabilities (Net)	0	0	0	0	0	0
Other Long Term Borrowings	0	0	0	0	0	1
Long Term Provisions	0	0	0	0	0	1
Total Non Current Liabilities	3	3	5	5	1	2
Short Term Borrowings	10	10	7	10	10	8
Trade Payables	18	33	26	25	27	31
Other Current Liabilities	3	3	7	2	1	2
Short Term Provisions	0	0	0	0	0	0
Total Current Liabilities	30	45	41	38	38	42
Total Equity and Liabilities	59	76	75	76	76	87
Fixed Assets	7	12	13	15	16	22
CWIP	4	1	2	1	-	-
Other Non Current Assets	0	0	0	1	2	1
Total Non Current Assets	14	17	19	17	18	23
Inventories	15	16	18	15	18	20
Trade Receivables	17	29	24	27	31	36
Cash & Cash Equivalents	1	1	1	3	2	2
Short Term Loans and Advances	12	13	13	12	6	0
Other Current Assets	1	1	1	2	1	8
Total Current Assets	46	59	57	59	59	65
Total Assets	59	76	75	76	76	87

Connect with us.

Medico Remedies Limited

1105/1106, Hubtown Solaris, N.S.Phadke Marg, opp.teligali, Andheri East, Mumbai-400069.

+91-22-26701055 /+91-22-26701066/+91-

22-68943803



info@medico.com

